CD274 and non-small cell lung carcinoma: Finally, a human IgG4 mAb targeted PD-1 (cemiplimab) has been approved for the treatment of advanced or metastatic NSCLC with PD-L1 expression ≥ 50%, based on the results of the phase III, EMPOWER-Lung 1 trial, in 2021 (Table 1) [50].